B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).

Autor: Balzarotti, Monica1 (AUTHOR), Brusamolino, Ercole1,2 (AUTHOR), Angelucci, Emanuele3 (AUTHOR), Carella, Angelo Michele4 (AUTHOR), Vitolo, Umberto5 (AUTHOR), Russo, Eleonora6 (AUTHOR), Congiu, Angelagiovanna4 (AUTHOR), Gotti, Manuel2 (AUTHOR), Massidda, Stefania3 (AUTHOR), Botto, Barbara5 (AUTHOR), Annechini, Giorgia6 (AUTHOR), Spina, Michele7 (AUTHOR), Re, Alessandro8 (AUTHOR), Zilioli, Vittorio Ruggero9 (AUTHOR), Merli, Francesco10 (AUTHOR), Salvi, Flavia11 (AUTHOR), Stelitano, Caterina12 (AUTHOR), Bonfichi, Maurizio2 (AUTHOR), Rodari, Marcello1 (AUTHOR), Murru, Roberta3 (AUTHOR)
Zdroj: Leukemia & Lymphoma. Oct2016, Vol. 57 Issue 10, p2375-2381. 7p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje